# LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

> **NCT06848465** · PHASE1 · RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 9 (estimated)

## Conditions studied

- Colorectal Cancer
- Liver Metastasis
- LDRT

## Interventions

- **RADIATION:** Low Dose Radiotherapy
- **RADIATION:** Short course Radiotherapy
- **DRUG:** XELOX
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06848465
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848465, "LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06848465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*